Navigation Links
Boston Heart Diagnostics Awarded $450,000 in Tax Incentives from the Massachusetts Life Sciences Center

FRAMINGHAM, Mass., March 19, 2013 /PRNewswire/ -- Boston Heart Diagnostics, a pioneer in personalized diagnostics and care plans for patients with or at risk for heart disease, has received $450,000 in tax incentives through the Life Sciences Tax Incentive Program, pledging to create 35 new Massachusetts jobs in 2013.  Boston Heart was one of just 25 companies to receive the tax incentive through the program, which is jointly administered by the Massachusetts Life Sciences Center and the Massachusetts Department of Revenue. Last year, the company received a $220,000 tax incentive through the program, pledging to create 31 Massachusetts full-time-equivalent (FTE) jobs in 2012; in fact the company added 55.

(Logo: )

"Boston Heart is the embodiment of what the Life Sciences Tax Incentive Program was designed to achieve, and we are very honored to have received this award, which will help us to continue to realize our ambitious growth goals," commented Boston Heart President and CEO Susan Hertzberg . "This past fall, we were honored to be named one of the top places to work in Massachusetts by the Boston Globe, and a 'Rising Star' winner for the Team Massachusetts Economic Impact Awards, which celebrates companies that have made outstanding contributions to the Massachusetts economy. We are extremely proud of these accomplishments, however, we are prouder still of the important difference we make every day in helping to improve the lives of patients – through our unique panels of diagnostic tests and patient wellness services. We are combining the very latest in diagnostics with a consumer-oriented mindset to create tools, including a patient portal and other mobile touch-points, that drive patient engagement in his or her own heart health and motivate the patient to comply with lifestyle changes that can reduce cardiovascular risk dramatically."

About Boston Heart Diagnostics (
Boston Heart Diagnostics focuses solely on cardiovascular disease – the number one cause of death in the United States. We offer clients an unparalleled combination of proprietary tests, actionable information, and dedicated service and support – partnering with healthcare providers so they can provide the best CVD patient care possible. There's much more to cardiovascular disease than "good" (HDL) and "bad" (LDL) cholesterol. Studies show that traditional statin drug therapy to lower LDL-C reduces the relative risk of heart attack by only 25%. Boston Heart, established in 2007, targets the 75% relative risk for a cardiovascular event that remains AFTER lowering LDL cholesterol. Our proprietary algorithm analyzes test results in light of relevant patient history and the latest peer-reviewed scientific data to produce personalized reports and plans that include specific therapeutic and lifestyle strategies tailored for each individual patient. When it comes to CVD management, Boston Heart Diagnostics is leading the charge to turn the promise of personalized medicine into a reality.

Media contact: Caroline Grossman -- 781.771.5579 --

SOURCE Boston Heart Diagnostics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Sanofi Signs Agreement for Type 1 Diabetes Research with Boston Academic Teaching Hospital
4. Alacrita Establishes U.S. Headquarters in Boston Area
5. BioBDx to Present at the 2012 BioPharm America and AdvaMed MedTech Conferences in Boston
6. Boston Childrens Hospital announces international genomics competition winner
7. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
8. Boston Scientific to Webcast Conference Call Discussing Fourth Quarter and Full Year 2012 Financial Results on January 29th
9. Boston College researchers unique nanostructure produces novel plasmonic halos
10. R&D, Innovation Key to Success - Research Report on Varian Medical Systems, Inc., Boston Scientific Corporation, Stryker Corporation, St. Jude Medical, Inc., and Thermo Fischer Scientific Inc.
11. Local Leaders Convene in Boston to Share Industry Best Practices in Second “Business of Big Data” Summit
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... uBiome, were featured on AngelList early in their initial angel funding process. Now, ... syndicate for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
(Date:11/24/2015)... Israel , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) ... on December 29, 2015 at 11:00 a.m. Israel ... Electra Tower, 98 Yigal Allon Street, 36 th Floor, ... of Eric Paneth and Izhak Tamir to the ... Rami Skaliter as external directors; , approval of an amendment to ...
Breaking Biology Technology:
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
Breaking Biology News(10 mins):